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Results. The dose administered was from 69.9 to 75.9Gy (average 74.2Gy), 5 days a week, in a fractionation of 2.3Gy per day (97%),
with 7 ﬁelds (97%) shaped three-dimensionally and photons of 18MV. The tolerance was excellent, showing no gastrointestinal
toxicity in 88.5%, G1 in 11.5%. Genitourinary toxicity was G0 in 55%, G1 in 40%, G2 in 5%.
Conclusion. The hypofractionated treatment is safe, showing minimal acute toxicity. Subsequently we will assess the long-term
toxicity, monitoring clinical and analytically through PSA control.
http://dx.doi.org/10.1016/j.rpor.2013.03.471
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Introduction. Despite recommendations in international guidelines, speciﬁc treatment depends on additional prognostic, clinical,
and personal factors. Relevant issues in the personalized treatment of high-risk prostate cancer (HRPC) include dose escalation,
treatment volumes, androgen deprivation therapy (ADT) strategy, and expected beneﬁts.
Objectives. To assess the recommendations of radiation oncologists in controversial areas of HRPC treatment.
Methods. The ÁGORA project involved 18 radiation oncologists and comprised 4 phases: (1) identiﬁcation of controversial areas
in the treatment of HRPC with aLHRH; (2) selection of speciﬁc literature; (3) preparation of case reports and questionnaires in 4
settings; (4) discussion of the case reports at regional meetings (May–July 2011). Therapeutic procedures were classiﬁed as “highly
recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion of the responses was
considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In young sexually active patients with HRPC (1 risk factor) and low IPSS, the most widely accepted treatment was neoadju-
vantHT (2–3months+ concomitant RT+adjuvantHT 24months) (SEM0.14). In young sexually active patientswithmoderate IPSS,
the consensus reached (SEM 0) was neoadjuvant HT 2–3 months+RT+adjuvant HT 24 months. In older, sexually inactive patients
with high IPSS, consensus was reached (SEM 0) on offering neoadjuvant HT 2–3 months+ concomitant treatment+adjuvant HT
24 months. In elderly patients with HRPC (1 risk factor) and a moderate post-TUR IPSS, the most accepted treatment (SEM 0.25)
was neoadjuvant HT 3 months+ concomitant ADT/RT.
Conclusions. Given the life expectancy of patients with HRPC, radiation oncologists agree that the ﬁrst option to be offered is
the combination of long-term HT combined with external RT. Treatment decisions in this group depend mainly on age and
unfavorable prognostic factors.
http://dx.doi.org/10.1016/j.rpor.2013.03.472
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Introduction. Both the CAPORT and AEU studies report a high prevalence of intermediate-risk prostate cancer (IRPC). Despite
recommendations in international guidelines, speciﬁc treatment depends on various prognostic, clinical, and personal factors.
Objectives. To assess radiation oncologists recommendations in controversial scenarios in IRPC and its treatment.
Methods. The ÁGORA project involved 18 radiation oncologists and comprised 4 phases: (1) identiﬁcation of controversial areas
in the treatment of IRPC with antigen deprivation (AD); (2) selection of speciﬁc literature; (3) preparation of case reports and
questionnaires in 4 settings; (4) discussion of the case reports at regional meetings (May–July 2011). Therapeutic procedures were
classiﬁed as “highly recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion
of the responses was considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In young sexually active patients with IRPC (1 factor) and low IPSS, the strongest agreement was for treatment consid-
ered inappropriate: Active monitoring and the combination of radiotherapy and bicalutamide 150mg/d. A broad consensus was
reached for radiotherapy combined with short-term AD and for brachytherapy. Consensus was weaker with respect to radical
prostatectomy and radiotherapy alone. In young sexually active patients with IRPC (>1 factor) and moderate IPSS, external radio-
therapy and short-term AD (4–6 months) was highly recommended. In older sexually inactive IRPC with a high IPSS, consensus
was reached on neoadjuvant AD 3 months+ concomitant radiotherapy. Brachytherapy alone should not be offered. No consensus
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was reached for elderly IRPC post-TUR patients with a moderate IPSS. Neoadjuvant AD 3 months+ concomitant external RT was
the most controversial option (SD 1.0)
Conclusions. Meeting the criteria for IRPC does not mean that treatment should be standardized. Until studies providing clear
evidence on this issue are published, these expert recommendations could serve as potential guidelines.
http://dx.doi.org/10.1016/j.rpor.2013.03.473
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Introduction. Recent reports of an association between androgen deprivation therapy (ADT) and increased risk of cardiovascular
events have generated debate on ADT in patients with cardiovascular comorbidities.
Objectives. To describe options recommended by radiation oncologists in the most controversial aspects of treating PC with ADT
in patients with cardiovascular risk factors.
Methods. The ÁGORA project involved 18 oncologists and comprised 4 phases: (1) selection by a panel of experts of the most
controversial aspects in the administration of ADT in patients with a cardiovascular history and PC; (2) selection of the most
relevant published scientiﬁc articles on this subject; (3) preparation of case reports and associated questionnaires; (4) critical
reading of the articles and discussion of the case reports at regional meetings. Therapeutic procedures were classiﬁed as “highly
recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion of the responses
was considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. The panel recommended that, in the absence of solid clinical evidence, patients with high- and very high-risk PC and
a history of severe cardiovascular disease should receive aLHRH in preference to other options. The panel also considered ADT
with aLHRH for 24-36 months combined with RT to be highly recommendable. In patients with intermediate-risk PC and a history
of cardiovascular disease, the panel considered ADT with aLHRH for 6-8 months in combination with RT and not administering
ADT to be highly recommendable approaches.
Conclusions. Speciﬁc studies are necessary to investigate the impact of ADT on cardiovascular mortality in patients who beneﬁt
most from adjuvant ADT in terms of survival. In the absence of such studies, the experts believe that published clinical evidence
on the proven therapeutic beneﬁts of ADT should override concerns about potential cardiovascular toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.474
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Introduction. Up to now, commercial atlases for automatic segmentation have been employed successfully in brain and head &
neck sites, for radiation therapy. To our knowledge no prostate atlas has been analyzed. Our objective is to show to what extent
prostate atlas can be used.
Methods. We used an evaluation version of Mimvista, that allows automatic contouring of volumes, by means of a library of 30
patients. For each patient, rectum, bladder, prostate and seminal vesicles were handmade deﬁned, whose deﬁnition was chosen
beforehand. For 10 patients, not included in the library, these organs where delineated by the radiation oncologist. MimVista
softwareusesmutual informationmatchingmetric anddeformation algorithms toﬁt the closest patient in the library to the target
patient, and then copy the contours. We check the accuracy visually, by an average distance between the compared contours,
and a conformality index (ratio of volume of intersection to manual delineated volume)
Results. Despite gas pockets, prostate and rectum scored better than the rest, due to differences in ﬁlling and use of stark contrast
(bladder) and due to the small volume (seminal vesicles). With mild contrast bladder scored at best (2.5mm distance difference).
Yet, for other organs, the average distance between contours could not be lowered under 3mm (5mm average). The time required
for automatic contouring was less than 1min.
